Your browser doesn't support javascript.
loading
Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study.
Khodaie, Faezeh; Moghadasi, Abdorreza Naser; Hosseinnataj, Abolfazl; Baghbanian, Seyed Mohammad; Ashtari, Fereshteh; Razazian, Nazanin; Poursadeghfard, Maryam; Majdi-Nasab, Nastaran; Hatamian, Hamidreza; Hoseini, Samaneh; Nahayati, Mohammad Ali; Nabavi, Seyed Massood; Faraji, Fardin; Harirchian, Mohammad Hossein; Mir, Nahid Hosseni Nejad; Moghadam, Nahid Beladi; Sharifipour, Ehsan; Bayati, Asghar; Kamali, Hoda; Mozhdehipanah, Hossein; Jalali, Nazanin; Abotorabi-Zarchi, Marzieh; Kamyari, Naser; Nikbakht, Roya; Azimi, Amirreza; Navardi, Samira; Heidari, Hora; Sahraian, Mohammad Ali; Eskandarieh, Sharareh.
Afiliação
  • Khodaie F; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Moghadasi AN; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Hosseinnataj A; Department of Biostatistics and Epidemiology, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
  • Baghbanian SM; Department of Neurology, Booalicina Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
  • Ashtari F; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Razazian N; Department of Neurology, School of Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Poursadeghfard M; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Majdi-Nasab N; Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Hatamian H; Department of Neurology, School of Medicine, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
  • Hoseini S; Department of Neurology, School of Medicine, Neurosciences Research Center, Aging Research Institute, Imam Reza Medical Research & Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Nahayati MA; Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Nabavi SM; Department of Regenerative Medicine, Royan Institute for Stem Cell Technology and Biology, Tehran, Iran.
  • Faraji F; Department of Neurology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
  • Harirchian MH; Department of Neurology, School of Medicine, Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Mir NHN; Department of Internal Medicine, School of Medicine, Shohadaye Ashayer Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran.
  • Moghadam NB; Department of Neurology, School of Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Sharifipour E; Department of Neurology, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Bayati A; Department of Neurology, Shahrekord University of Medical Sciences and Health Services, Shahrekord, Iran.
  • Kamali H; Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
  • Mozhdehipanah H; Department of Neurology, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Jalali N; Department of Neurology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
  • Abotorabi-Zarchi M; Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Kamyari N; Department of Biostatistics and Epidemiology, School of Health, Abadan University of Medical Sciences, Abadan, Iran.
  • Nikbakht R; Department of Biostatistics and Epidemiology, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
  • Azimi A; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Navardi S; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Heidari H; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Sahraian MA; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Eskandarieh S; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: sh_eskandarieh@yahoo.com.
Clin Neurol Neurosurg ; 239: 108221, 2024 04.
Article em En | MEDLINE | ID: mdl-38447483
ABSTRACT

OBJECTIVE:

The time to diagnosis of multiple sclerosis (MS) is of great importance for early treatment, thereby reducing the disability and burden of the disease. The purpose of this study was to determine the time from the onset of clinical symptoms to the diagnosis of MS and to evaluate the factors associated with a late diagnosis in Iranian MS patients.

METHODS:

The present cross-sectional study was conducted on patients with MS who were registered in the National MS Registry System of Iran (NMSRI).

RESULTS:

Overall, 23291 MS patients registered in 18 provinces of Iran were included in this study. The mean (standard deviation) interval between the onset of the disease and diagnosis of MS was 13.42 (32.40) months, and the median was one month. The diagnostic interval of 41.6% of patients was less than one month, and 14.8% of them had a one-month time to diagnosis. Patients with an age of onset below 18 years and those diagnosed after the age of 50 years had a longer time to diagnosis (P<0.001). Patients with primary progressive MS (PPMS) had the longest time to diagnose and those with relapsing-remitting MS (RRMS) had the shortest time (P<0.001). The results of negative binominal regression showed that the average rate of delay in diagnosis in women was 12% less than that in men. The average delay in diagnosis in patients with a positive family history of MS was 23% more than that in others. The rate of delay in the diagnosis of patients with PPMS and secondary progressive MS was 2.22 and 1.66 times higher, respectively, compared with RRMS.

CONCLUSION:

The findings of the present study revealed that more than half of the MS patients were diagnosed within a one-month interval from the symptom onset, which is an acceptable period. More attention should be paid to patients' access to medical facilities and MS specialists.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Limite: Adolescent / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Limite: Adolescent / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article